SPRB — Spruce Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $28.81m
- -$64.19m
- $10.09m
- 21
- 45
- 24
- 21
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 10.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 13.1 | 29.4 | 42.1 | 47.3 | 62.1 |
Operating Profit | -13.1 | -29.4 | -42.1 | -47.3 | -52 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -13.1 | -29.5 | -42.3 | -46.2 | -47.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.1 | -29.5 | -42.3 | -46.2 | -47.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.1 | -29.5 | -42.3 | -46.2 | -47.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.1 | -29.5 | -42.3 | -46.2 | -47.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.588 | -1.33 | -1.81 | -1.96 | -1.24 |
Dividends per Share |